Dose Escalation Study of KW-3902 on Diuresis in Subjects With Congestive Heart Failure (CHF).

Inclusion Criteria: * History of CHF for greater than 3 months, * Receiving oral/IV diuretic therapy * Hospitalized for therapy for HF and edema that has not responded to diuretic therapy. * Signs and symptoms of ongoing volume overload Exclusion Criteria: * Myocardial infarction in past 14 days * Clinical evidence of acute coronary syndrome causing worsening of HF, * Pregnant or breast-feeding, * Severe, uncorrected primary valvular disease, constrictive pericarditis, restrictive or hypertrophic cardiomyopathy, * Automated implanted cardiac defibrillator (AICD) or synchronization device implanted within the preceding 7 days, * Require mechanical ventilation, ultrafiltration, or hemodialysis at the time of enrollment, * Deterioration due to an acute or superimposed condition requiring therapy other than diuretics * Symptomatic ventricular tachycardia, * Severe concomitant primary hepatic disease, * Severe pulmonary disease, * Any other concomitant life-threatening disease, * CVA in the preceding 6 months, * Hypotension, * Participated in another clinical trial within 30 days, * Acute contrast nephropathy, * Admitted for heart transplant surgery or have had a heart transplant.